https://www.selleckchem.com/pr....oducts/Pyroxamide(NS
5%) in the weight-based cohort (hazard ratio [HR] = 0.73; 95% CI = 0.57-0.93; = 0.01). When death was removed from the composite end point, there was no significant difference between the cohorts in recurrent VTE or major bleed (HR = 1.18; = 0.38). In the anti-Xa cohort, a total of 1584 anti-Xa peak levels were collected, with 1324 (83.6%) drawn correctly in relation to enoxaparin administration. Of those, 714 (53.9%) were within therapeutic range. Patients with cancer receiving anti-Xa-guided enoxaparin dose adjustments
Curtir
Comentario
Compartilhar
